
Cardiac patients receiving nasal gel showed reduction of S. aureus
Destiny Pharma, a clinical stage biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has released data from its recent Phase IIb clinical trial. In March 2021, the company announced that this study had met its primary endpoint, demonstrating a reduction of 2.5 log… Read More













